Benjamin L. Oakes

PRESIDENT, CEO · SCRIBE THERAPEUTICS, INC. · CIK 0002127814

FILING MIX · LIFETIME100%/0%

BUYS

SELLS

TOTAL VALUE

COMPANIES

ACTIVE SINCE

Mar 2026

HOLDINGS NOW

429,599

AVG SELL PX

—

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

No backtest data available for Benjamin L. Oakes. Backtests are computed for purchase (P) and sale (S) transactions with resolvable price history.

Holdings over time

SCTX · 429,599 shares · as of Jul 23, 2026

Trading cadence · quarterly flow

BUY ● SELL ●

2026

FLOW · 3 buys / 0 sellsCOVERAGE · 3 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
SCTX SCRIBE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	429,599	—	—	429,599	Jul 23, 2026	Jul 27, 2026 ↗	View →
SCTX SCRIBE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	264,784	—	—	264,784	Jul 23, 2026	Jul 27, 2026 ↗	View →
SCTX SCRIBE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	12,969	—	—	12,969	Mar 13, 2026	Jul 27, 2026 ↗	View →

Other insiders · SCTX

Loading peer insiders…

About this filer

CIK 0002127814

ROLE

President, CEO

PRIMARY

SCTX

COMPANIES

ACTIVE SINCE

Mar 2026

MARKETPEEL · /INSIDER/0002127814DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

The morning brief, before the bell.